# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Acasti Pharma (NASDAQ:ACST) reported quarterly losses of $(0.21) per share. This is a 59.62 percent increase over losses of $(0...
Craig-Hallum analyst Chase Knickerbocker initiates coverage on Acasti Pharma (NASDAQ:ACST) with a Buy rating and announces P...
The poster, Safety and Tolerability of Intravenous Versus Enteral Nimodipine in Patients with Aneurysmal Subarachnoid Hemorrhag...
Shares of KeyCorp (NYSE: KEY) moved lower during Thursday’s session after the company reported fourth-quarter financial results...
-SEC Filing